Posted On: 07/02/2015 12:05:57 PM
Post# of 579
ACXA Election of Director
On July 1, 2015, the Board of Directors of the Company appointed Mr. William Callahan to serve as Director of the Company’s Board, effective immediately.
Mr. Callahan (age 56) has spent most of his more than 30-year career in emerging growth companies in the medical device, drug delivery and pharmaceutical industry, establishing and growing operations groups, and participating in the launch of numerous new products. Mr. Callahan has experience in the translation of research and development projects into commercially viable products, commercial development of new products, set-up of quality control procedures and documentation, and operations. He has been Senior Director Manufacturing Operations at AcelRx since March 2014. He was a director of the Company’s board from January 2013 until March 2014, and was a consultant to the pharmaceutical and medical technology industries from February 2012 until March 2014. From October 2009 until February 2012, he was Vice President Operations for Depomed, Inc. His previous tasks have included establishing GMP manufacturing operations and engineering groups whose responsibilities covered product assembly/manufacturing, process and product development, scale up and technology transfer activities, equipment and process qualification and validation execution, and support of regulatory FDA submissions. Commercial products that he worked on include in-vitro diagnostic devices (Lifescan and Avocet Medical Inc.), medical equipment (Applied Biosystems), transdermal pharmaceutical products (Cygnus Therapeutics), and solid oral drug delivery products (Depomed, Inc). Throughout his career he has held positions of increasing responsibility in engineering and operations groups at Lifescan – a Johnson & Johnson Co., Applied Biosystems, Cygnus Therapeutics, Avocet Medical, and Depomed, Inc. He received a B.S. degree in Chemistry from San Francisco State University.
Retirement of Director
On July 1, 2015, Mr. Luc H. Meyer retired as Director of the Company’s Board, effective immediately. Mr. Meyer’s retirement does not arise from any disagreement on any matter relating to the Company’s operations, policies or practices, or regarding the general direction of the Company.
On July 1, 2015, the Board of Directors of the Company appointed Mr. William Callahan to serve as Director of the Company’s Board, effective immediately.
Mr. Callahan (age 56) has spent most of his more than 30-year career in emerging growth companies in the medical device, drug delivery and pharmaceutical industry, establishing and growing operations groups, and participating in the launch of numerous new products. Mr. Callahan has experience in the translation of research and development projects into commercially viable products, commercial development of new products, set-up of quality control procedures and documentation, and operations. He has been Senior Director Manufacturing Operations at AcelRx since March 2014. He was a director of the Company’s board from January 2013 until March 2014, and was a consultant to the pharmaceutical and medical technology industries from February 2012 until March 2014. From October 2009 until February 2012, he was Vice President Operations for Depomed, Inc. His previous tasks have included establishing GMP manufacturing operations and engineering groups whose responsibilities covered product assembly/manufacturing, process and product development, scale up and technology transfer activities, equipment and process qualification and validation execution, and support of regulatory FDA submissions. Commercial products that he worked on include in-vitro diagnostic devices (Lifescan and Avocet Medical Inc.), medical equipment (Applied Biosystems), transdermal pharmaceutical products (Cygnus Therapeutics), and solid oral drug delivery products (Depomed, Inc). Throughout his career he has held positions of increasing responsibility in engineering and operations groups at Lifescan – a Johnson & Johnson Co., Applied Biosystems, Cygnus Therapeutics, Avocet Medical, and Depomed, Inc. He received a B.S. degree in Chemistry from San Francisco State University.
Retirement of Director
On July 1, 2015, Mr. Luc H. Meyer retired as Director of the Company’s Board, effective immediately. Mr. Meyer’s retirement does not arise from any disagreement on any matter relating to the Company’s operations, policies or practices, or regarding the general direction of the Company.
(0)
(0)
